Ioanna Bazdiara
Overview
Explore the profile of Ioanna Bazdiara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
26
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spanoudakis E, Papoutselis M, Bazdiara I, Lamprianidi E, Kordella X, Tilkeridis C, et al.
Mediterr J Hematol Infect Dis
. 2018 Nov;
10(1):e2018058.
PMID: 30416690
is a gain of function point mutation that occurs in Myeloproliferative Neoplasm (MPN) patients and deranges their hemopoiesis at cellular level. We speculate that hyperfunctioning JAK2 can modify osteoclast (OCL)...
2.
Spanoudakis E, Bazdiara I, Pantelidou D, Kotsianidis I, Papadopoulos V, Margaritis D, et al.
Leuk Res
. 2010 Sep;
35(4):459-64.
PMID: 20828816
Telomere exhaustion and increased telomerase activity are associated with the acquisition of aggressive molecular events in a variety of haematological malignancies. In Philadelphia chromosome negative myeloproliferative neoplasms (Ph(neg)MPN's), telomere dynamics...
3.
Spanoudakis E, Bazdiara I, Kotsianidis I, Margaritis D, Goutzouvelidis A, Christoforidou A, et al.
Ann Hematol
. 2008 Dec;
88(7):629-32.
PMID: 19096846
Ph-negative chronic myeloproliferative disorders (Ph(neg)cMPD) are treated according to the estimated vascular risk. The recent discovery of V617F point mutation of the JAK2 kinase, which frequently occurs in these diseases,...
4.
Kotsianidis I, Bazdiara I, Anastasiades A, Spanoudakis E, Pantelidou D, Margaritis D, et al.
Acta Haematol
. 2008 Oct;
120(1):51-6.
PMID: 18824842
Background: Farnesyltransferase inhibitors (FTIs) target proteins needing prenylation for functioning. Tipifarnib (Zarnestra), a potent and specific inhibitor of farnesyltransferase, showed considerable activity in phase I and II studies in myelodysplastic...